Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02370329 · ClinicalTrials.gov registry record · Phase 2
P1101 in Treating Patients With Myelofibrosis
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT02370329: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT02370329 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02370329, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This pilot phase II trial studies P1101 (polyethyleneglycol \[PEG\]-proline-interferon alpha-2b) in treating patients with myelofibrosis. PEG-proline-interferon alpha-2b is a substance that can improve the body's natural response and may slow the growth of myelofibrosis.
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Ropeginterferon Alfa-2B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-08-12 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02370329
The ClinicalTrials.gov registry entry for NCT02370329 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02370329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02370329 about?
NCT02370329 is a clinical study titled "P1101 in Treating Patients With Myelofibrosis". This pilot phase II trial studies P1101 (polyethyleneglycol \[PEG\]-proline-interferon alpha-2b) in treating patients with myelofibrosis. PEG-proline-interferon alpha-2b is a substance that can improve the body's natural response and may slow the growth of myelofibrosis.
What is the current status of trial NCT02370329?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2015-08-12. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT02370329?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Ropeginterferon Alfa-2B (BIOLOGICAL).
Who is sponsoring clinical trial NCT02370329?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.